12:00 AM
 | 
Aug 20, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

AZD5213: Phase II started

In its 2Q12 earnings, AstraZeneca said that last quarter it began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate 3 doses...

Read the full 86 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >